<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Peroxisome Biogenesis Disorder - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Peroxisome Biogenesis Disorder</span>
        </nav>

        <header class="page-header">
            <h1>Peroxisome Biogenesis Disorder</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0019234" target="_blank">
                        MONDO:0019234
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Peroxisomal Disorder</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">15</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">10</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Classifications -->
        

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">âš™</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">11</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Peroxisome Biogenesis Defect</div>
                
                <div class="item-desc">Mutations in PEX genes disrupt the assembly and function of peroxisomes, leading to impaired metabolic processes.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33417206" target="_blank">PMID:33417206</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Impaired peroxisome biogenesis, including defects of membrane assembly, import of peroxisomal matrix proteins, and division of peroxisome, causes peroxisome biogenesis disorders (PBDs)."</div>
                
                
                <div class="evidence-explanation">This reference highlights that mutations affecting peroxisome biogenesis lead to dysfunction of peroxisomes and consequently to metabolic impairments.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28409474" target="_blank">PMID:28409474</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"More than a dozen complementation groups of animal somatic mutant cells defective in peroxisome biogenesis have been successfully isolated in Chinese hamster ovary (CHO) cells and used as a model system reflecting fatal human severe genetic disorders named peroxisome biogenesis disorders (PBD)."</div>
                
                
                <div class="evidence-explanation">Defective peroxisome biogenesis due to mutations in PEX genes supports the statement about peroxisomal disorders and impaired metabolic processes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28320181" target="_blank">PMID:28320181</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peroxisome biogenesis factor 10 (PEX10) is involved in the import of peroxisomal matrix proteins, and the mutation of this gene causes 3 subtypes of peroxisome biogenesis disorders..."</div>
                
                
                <div class="evidence-explanation">The reference details how mutations in PEX10 affect peroxisomal import, aligning with the statement&#39;s assertion about disrupted peroxisome function.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Accumulation of Toxic Metabolites</div>
                
                <div class="item-desc">The inability to break down very long-chain fatty acids (VLCFAs) and other compounds leads to their accumulation in tissues.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        fatty acid beta-oxidation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006635" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        very long-chain fatty acid metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000038" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19933170" target="_blank">PMID:19933170</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peroxisomes are vital eukaryotic organelles that participate in lipid metabolism, in particular the metabolism of very-long-chain fatty acids (VLCFA)... including impaired peroxisomal protein import, elevated VLCFA levels and growth retardation."</div>
                
                
                <div class="evidence-explanation">The reference supports the accumulation of VLCFAs as part of the pathophysiology of Peroxisome Biogenesis Disorders but does not mention bile acid intermediates or phytanic acid.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3119940" target="_blank">PMID:3119940</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In patients with cerebro-hepato-renal (Zellweger) syndrome, the absence of peroxisomes results in an impairment of metabolic processes... These include the catabolism of very long chain (greater than C22) fatty acids... the catabolism of phytanic acid and the catabolism of pipecolic acid."</div>
                
                
                <div class="evidence-explanation">This reference supports the accumulation of VLCFAs and phytanic acid in peroxisomal disorders but does not mention bile acid intermediates.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22978395" target="_blank">PMID:22978395</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"By comparing the different peroxisomal disorders, we provide evidence suggesting that the main hepatotoxic metabolites responsible for the liver pathology found in patients, are the bile acid synthesis intermediates di- and trihydroxycholestanoic acid (DHCA and THCA)."</div>
                
                
                <div class="evidence-explanation">This reference supports the accumulation of bile acid intermediates in peroxisomal disorders but does not mention VLCFAs or phytanic acid.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Deficiency of Essential Compounds</div>
                
                <div class="item-desc">Impaired synthesis of plasmalogens and other essential compounds disrupts normal cellular functions.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        ether lipid biosynthetic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008611" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        bile acid biosynthetic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006699" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36720320" target="_blank">PMID:36720320</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The absence of plasmalogens in several organs of patients with deficiency in peroxisome biogenesis suggests that de novo synthesis of plasmalogens contributes significantly to plasmalogen homeostasis in humans."</div>
                
                
                <div class="evidence-explanation">The literature indicates that plasmalogen biosynthesis is significantly affected in patients with peroxisome biogenesis disorders, which supports the statement regarding impaired synthesis of plasmalogens disrupting normal cellular functions.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32165495" target="_blank">PMID:32165495</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The peroxisome is a subcellular organelle that functions in essential metabolic pathways, including biosynthesis of plasmalogens, fatty acid beta-oxidation of very-long-chain fatty acids, and degradation of hydrogen peroxide. Peroxisome biogenesis disorders (PBDs) manifest as severe dysfunction..."</div>
                
                
                <div class="evidence-explanation">This study reinforces that impaired peroxisome function, including the biosynthesis of plasmalogens, leads to a broad spectrum of cellular dysfunctions.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33417206" target="_blank">PMID:33417206</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peroxisomes are presented in all eukaryotic cells and play essential roles in many of lipid metabolic pathways, including beta-oxidation of fatty acids and synthesis of ether-linked glycerophospholipids, such as plasmalogens."</div>
                
                
                <div class="evidence-explanation">The abstract confirms that peroxisomes are crucial for the synthesis of plasmalogens and that their dysfunction could disrupt normal cellular functions.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neurological Dysfunction</div>
                
                <div class="item-desc">Accumulation of toxic metabolites and deficiency of essential compounds lead to demyelination, neuronal migration defects, and neurodegeneration.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        oligodendrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000128" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15868469" target="_blank">PMID:15868469</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peroxisome biogenesis disorders, of which Zellweger syndrome is the most severe, result in severe neurological dysfunction associated with abnormal CNS neuronal migrations due to the lack of functional peroxisomes."</div>
                
                
                <div class="evidence-explanation">The reference specifies that a lack of functional peroxisomes leads to severe neurological dysfunction, including demyelination and defects in neuronal migration, which aligns with the statement&#39;s content.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33417206" target="_blank">PMID:33417206</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Impaired peroxisome biogenesis, including defects of membrane assembly, import of peroxisomal matrix proteins, and division of peroxisome, causes peroxisome biogenesis disorders (PBDs)."</div>
                
                
                <div class="evidence-explanation">This reference describes PBDs leading to significant neurodegeneration and psychomotor dysfunction, consistent with the statement on neurological dysfunction due to the disorder.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22978395" target="_blank">PMID:22978395</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Liver pathology is a frequent finding in patients affected by a peroxisomal disorder. ... we provide evidence suggesting that the main hepatotoxic metabolites responsible for the liver pathology found in patients, are the bile acid synthesis intermediates di- and trihydroxycholestanoic acid..."</div>
                
                
                <div class="evidence-explanation">While this reference supports the role of toxic metabolites, it focuses on liver pathology rather than CNS-specific features like demyelination and neuronal migration defects.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Hepatic Dysfunction</div>
                
                <div class="item-desc">Accumulation of bile acid intermediates and VLCFAs, along with oxidative stress, cause hepatomegaly, fibrosis, and liver failure.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        hepatocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000182" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12473763" target="_blank">PMID:12473763</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Common to these three disorders are liver disease, variable neurodevelopmental delay, retinopathy, and perceptive deafness."</div>
                
                
                <div class="evidence-explanation">The study mentions liver disease as a common symptom of peroxisome biogenesis disorder (PBD), supporting hepatic dysfunction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22978395" target="_blank">PMID:22978395</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The main hepatotoxic metabolites responsible for the liver pathology found in patients, are the bile acid synthesis intermediates di- and trihydroxycholestanoic acid (DHCA and THCA)."</div>
                
                
                <div class="evidence-explanation">This reference supports the accumulation of bile acid intermediates causing liver pathology in PBDs.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29282281" target="_blank">PMID:29282281</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"They are caused by mutations of peroxisomal biogenesis factors encoded by Pex genes, and result in childhood lethality"</div>
                
                
                <div class="evidence-explanation">This reference indirectly supports the statement by discussing the lethal and severe impact of PBDs, including liver dysfunction.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Skeletal Abnormalities</div>
                
                <div class="item-desc">Plasmalogen deficiency disrupts normal bone formation, leading to rhizomelic shortening of limbs and chondrodysplasia punctata.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10904262" target="_blank">PMID:10904262</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum disease and rhizomelic chondrodysplasia punctata are progressive disorders characterized by loss of multiple peroxisomal metabolic functions."</div>
                
                
                <div class="evidence-explanation">The context indicates that rhizomelic chondrodysplasia punctata (a type of peroxisome biogenesis disorder) results from peroxisomal dysfunction, supporting the connection between plasmalogen deficiency and skeletal abnormalities, including rhizomelic shortening of limbs and chondrodysplasia punctata.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10972423" target="_blank">PMID:10972423</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The case of a Yemeni girl with isolated peroxisomal acyl-CoA:dihydroxyacetonephosphate acyltransferase (DHAPAT) deficiency is reported. She had rhizomelic chondrodysplasia punctata, microcephaly, failure to thrive, delayed motor and mental development, and spastic quadriplegia."</div>
                
                
                <div class="evidence-explanation">The document discusses a case where plasmalogen biosynthesis deficiency leads to rhizomelic chondrodysplasia punctata, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8507680" target="_blank">PMID:8507680</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The results have clearly shown an indispensable role for peroxisomes in the total process of ether lipid synthesis as evidenced by a description of the cellular topography of this process."</div>
                
                
                <div class="evidence-explanation">The paper supports the importance of peroxisomes in lipid synthesis, including plasmalogens, which are associated with diseases like rhizomelic chondrodysplasia punctata that impact bone and cartilage formation.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Multisystem Involvement</div>
                
                <div class="item-desc">The pervasive nature of peroxisomal dysfunction affects multiple organ systems, resulting in a wide range of clinical manifestations.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14527301" target="_blank">PMID:14527301</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The multisystem clinical phenotype varies widely in severity and results from disturbances in both development and metabolic homeostasis."</div>
                
                
                <div class="evidence-explanation">This statement supports the pervasive nature of peroxisomal dysfunction affecting multiple organ systems, leading to a range of clinical manifestations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33417210" target="_blank">PMID:33417210</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peroxisomopathies are rare diseases due to dysfunctions of the peroxisome in which this organelle is either absent or with impaired activities. These diseases... affect the central and peripheral nervous system."</div>
                
                
                <div class="evidence-explanation">This statement aligns with the notion that peroxisomal dysfunction affects multiple organ systems.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26453805" target="_blank">PMID:26453805</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The peroxisomal compartment in hepatocytes hosts several essential metabolic conversions. These are defective in peroxisomal disorders... including mitochondria and the ER."</div>
                
                
                <div class="evidence-explanation">This reference details the involvement of multiple cellular compartments and metabolic pathways, illustrating multisystem impact.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Microglial Dysfunction and Neuroinflammation</div>
                
                <div class="item-desc">Peroxisomal defects in microglial cells induce a disease-associated microglial (DAM) signature with altered lipid metabolism, lipid droplet accumulation, and impaired autophagy, contributing to neurodegeneration.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        microglial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000129" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Peroxisome-Organelle Crosstalk Disruption</div>
                
                <div class="item-desc">Disruption of peroxisome-ER-mitochondria interactions impairs lipid trafficking and metabolic coordination, particularly affecting VLCFA and ether-lipid flux between organelles.</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Retinal Pigment Epithelium Dysfunction</div>
                
                <div class="item-desc">In peroxisome biogenesis disorders, retinal pigment epithelium shows progressive lipid remodeling with decreased plasmalogens and increased very-long-chain lysophosphatidylcholines, leading to structural degeneration and vision loss.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        retinal pigment epithelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002586" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        photoreceptor cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000210" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired Peroxisome Biogenesis and Import</div>
                
                <div class="item-desc">Mutations in PEX genes disrupt the peroxisomal protein import machinery, including PEX5/PEX7 receptors, the PEX13/PEX14 docking complex, and the PEX1-PEX6 AAA+ ATPase export complex, preventing proper assembly and function of peroxisomes.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        protein import into peroxisome matrix
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0016558" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        peroxisome organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007031" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">â¬¡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Heart_Failure[&#34;Heart Failure&#34;]
    Cardiomyopathy[&#34;Cardiomyopathy&#34;]

    Cardiomyopathy --&gt; Heart_Failure

    style Heart_Failure fill:#fef3c7
    style Cardiomyopathy fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">â—</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">15</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hypotonia
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001252" target="_blank">
                            HP:0001252
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7685145" target="_blank">PMID:7685145</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"These disorders should be considered in the differential diagnosis of the infant with hypotonia and psychomotor delay..."</div>
                
                
                <div class="evidence-explanation">The reference mentions hypotonia as a significant clinical feature in peroxisomal disorders.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28320181" target="_blank">PMID:28320181</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"...suggest that these PEX10 mutations involve not only cerebellar but also more multiple nervous systems..."</div>
                
                
                <div class="evidence-explanation">While the reference primarily discusses cerebellar involvement, it indirectly supports the statement by implicating neurological systems in PEX10-related peroxisome biogenesis disorders.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/13129589" target="_blank">PMID:13129589</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The floppy infant syndrome is a well-recognized entity for pediatricians and neonatologists. The condition refers to an infant with generalized hypotonia..."</div>
                
                
                <div class="evidence-explanation">The reference directly supports the very frequent occurrence of hypotonia in infants with peroxisomal disorders.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Developmental Delay
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001263" target="_blank">
                            HP:0001263
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7685145" target="_blank">PMID:7685145</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Because peroxisomes are involved in the metabolism of lipids critical to the functioning of the nervous system, many of the peroxisomal disorders manifest with significant degrees of progressive psychomotor dysfunction."</div>
                
                
                <div class="evidence-explanation">The literature indicates that peroxisomal disorders, which include Peroxisome Biogenesis Disorders (PBDs), frequently present with progressive psychomotor dysfunction, supporting the statement that developmental delay is a very frequent neurologic phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36293220" target="_blank">PMID:36293220</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The clinical presentation of PBDs may range from severe, lethal multisystemic disorders to milder, late-onset disease. The vast majority of PBDs belong to Zellweger Spectrum Disordes (ZSDs) and represents a continuum of overlapping clinical symptoms."</div>
                
                
                <div class="evidence-explanation">Although this does not explicitly mention developmental delay, the overall description implies a frequent occurrence of neurologic dysfunction, which is often tied to developmental delays.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11769739" target="_blank">PMID:11769739</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Distinctive external features are variable among these three disorders, and neurologic deficit has its onset at birth or in infancy."</div>
                
                
                <div class="evidence-explanation">The article describes neurologic deficits appearing early in life, which aligns with developmental delays being a very frequent phenotype.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Seizures
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                            HP:0001250
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Common in severe forms, particularly neonatal Zellweger syndrome</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Leukodystrophy
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002415" target="_blank">
                            HP:0002415
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">White matter degeneration due to myelin lipid dependency on peroxisomal function</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hepatomegaly
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Hepatobiliary</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002240" target="_blank">
                            HP:0002240
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31005404" target="_blank">PMID:31005404</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Inherited metabolic diseases account for about one third of pediatric patients with hepatomegaly, acute liver failure, cirrhosis or cholestasis."</div>
                
                
                <div class="evidence-explanation">The reference states that inherited metabolic diseases, which include peroxisome biogenesis disorders, account for a substantial portion of pediatric hepatomegaly cases but does not specify the frequency as &#39;frequent.&#39;</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22978395" target="_blank">PMID:22978395</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Liver pathology is a frequent finding in patients affected by a peroxisomal disorder."</div>
                
                
                <div class="evidence-explanation">The reference mentions liver pathology as frequent but does not specifically state hepatomegaly.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26615381" target="_blank">PMID:26615381</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"ZS is a peroxisomal disorder with a multiple congenital anomalies, characterized by stereotypical facies, profound hypotonia, organ involvement including cerebral, retinal, hepatic, and renal."</div>
                
                
                <div class="evidence-explanation">The reference discusses organ involvement including hepatic involvement but does not specify hepatomegaly as frequent.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Cholestasis
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Hepatobiliary</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001396" target="_blank">
                            HP:0001396
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Due to bile acid biosynthetic block and hepatic lipid handling deficits</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Renal Dysfunction
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Renal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012622" target="_blank">
                            HP:0012622
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Variable kidney dysfunction across the spectrum</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Retinopathy
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Visual</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000488" target="_blank">
                            HP:0000488
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31884631" target="_blank">PMID:31884631</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Retinopathy is a recurrent feature in both the severely and mildly affected patients, which can be accompanied with other ophthalmological pathologies."</div>
                
                
                <div class="evidence-explanation">The study states that retinopathy is a recurrent feature in patients with peroxisomal disorders, supporting the statement that visual phenotypes, specifically retinopathy, are frequent.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12473763" target="_blank">PMID:12473763</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Common to these three disorders are liver disease, variable neurodevelopmental delay, retinopathy, and perceptive deafness."</div>
                
                
                <div class="evidence-explanation">The study indicates that retinopathy is common in peroxisome biogenesis disorders like Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease, supporting the frequent occurrence of retinopathy as a visual phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35227579" target="_blank">PMID:35227579</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Retinal degeneration with or without optic atrophy is the most frequent phenotype, followed by oculomotor problems, involvement of the cornea and lens, and refractive errors."</div>
                
                
                <div class="evidence-explanation">The study states that retinal degeneration is the most frequent ocular phenotype observed in inherited metabolic disorders, which includes peroxisome biogenesis disorders, thereby supporting the frequent occurrence of retinopathy.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hearing Loss
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Auditory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000365" target="_blank">
                            HP:0000365
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34534157" target="_blank">PMID:34534157</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The majority of PBD-ZSD patients in this study presented with moderately-severe to severe hearing loss."</div>
                
                
                <div class="evidence-explanation">This study characterizes hearing loss as a common phenotype in patients with Peroxisome Biogenesis Disorder within the Zellweger Spectrum.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36291074" target="_blank">PMID:36291074</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peroxisome biogenesis disorders (due to PEX gene mutations) are associated with symptoms that range in severity and can lead to early childhood death, but a common feature is hearing impairment."</div>
                
                
                <div class="evidence-explanation">This study also confirms hearing impairment as a frequent phenotype in Peroxisome Biogenesis Disorders, further supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33417209" target="_blank">PMID:33417209</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Heimler syndrome is a rare syndrome associating sensorineural hearing loss with retinal dystrophy and amelogenesis imperfecta due to PEX1 or PEX6 biallelic pathogenic variations. This syndrome is one of the less severe forms of peroxisome biogenesis disorders."</div>
                
                
                <div class="evidence-explanation">Heimler syndrome, a less severe form of peroxisome biogenesis disorders, frequently presents with sensorineural hearing loss, further supporting the frequent association of hearing loss with these disorders.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Craniofacial Dysmorphism
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Craniofacial</span>
                    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23671347" target="_blank">PMID:23671347</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with ZS present in the neonatal period with a characteristic phenotype of distinctive facial stigmata."</div>
                
                
                <div class="evidence-explanation">Distinctive facial stigmata can be considered a form of craniofacial dysmorphism, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1710072" target="_blank">PMID:1710072</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Zellweger syndrome, the most lethal of the three peroxisomal biogenesis disorders, causes infantile hypotonia, seizures, and death within the first year."</div>
                
                
                <div class="evidence-explanation">While the text does not explicitly mention craniofacial dysmorphism, the severity of symptoms and multisystem involvement suggest potential craniofacial manifestations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Adrenal Insufficiency
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Endocrine</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000846" target="_blank">
                            HP:0000846
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Due to adrenal gland dysfunction</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36649687" target="_blank">PMID:36649687</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Primary adrenal insufficiency is common in patients with PD. Based on our data, patients with the compound heterozygous PEX1 pathogenic variants of exon 13 (c.2097dupT and c.2528G&gt;A) tend to have adrenal insufficiency."</div>
                
                
                <div class="evidence-explanation">The study indicates that primary adrenal insufficiency is frequent in patients with peroxisomal disorders, specifically those with PEX1 pathogenic variants.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25179809" target="_blank">PMID:25179809</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Primary adrenal insufficiency was found in 7/24 patients examined, with 4/7 being asymptomatic. Systematic evaluation of adrenal function, through a Synacthen test, should be included in the clinical management of these patients."</div>
                
                
                <div class="evidence-explanation">The study highlights a high prevalence of primary adrenal insufficiency in patients with Zellweger spectrum disorders, which are a type of peroxisome biogenesis disorder.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Chondrodysplasia Punctata
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                </div>
                
                <div class="item-desc">Stippling of epiphyses on X-rays</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10904262" target="_blank">PMID:10904262</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum disease and rhizomelic chondrodysplasia punctata are progressive disorders characterized by loss of multiple peroxisomal metabolic functions."</div>
                
                
                <div class="evidence-explanation">Rhizomelic chondrodysplasia punctata is a type of peroxisome biogenesis disorder, supporting the statement that chondrodysplasia punctata falls under the category of musculoskeletal issues associated with peroxisome biogenesis disorders.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24030027" target="_blank">PMID:24030027</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We present a 2-month-old male affected by Zellweger syndrome, a rare peroxisomal disorder. The diagnosis was supported by clinical and radiological findings and established by biochemical tests. The characteristic radiological features included anomalous ossification (epiphyseal stippling)."</div>
                
                
                <div class="evidence-explanation">This study supports the statement by indicating that epiphyseal stippling (chondrodysplasia punctata) is a characteristic feature in Zellweger syndrome, a type of peroxisome biogenesis disorder.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17671048" target="_blank">PMID:17671048</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Classic rhizomelic chondrodysplasia punctata is a rare, autosomal, recessively inherited disorder that is characterized by proximal shortening of the limbs, punctuate calcifications of the epiphyses, cataracts, developmental delay, and early lethality."</div>
                
                
                <div class="evidence-explanation">Rhizomelic chondrodysplasia punctata is characterized by punctuate calcifications of the epiphyses, supporting the statement that this condition is associated with peroxisome biogenesis disorders and involves stippling of epiphyses.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Thrombocytopenia
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Hematologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001873" target="_blank">
                            HP:0001873
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Low platelet count</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27941306" target="_blank">PMID:27941306</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peroxisome is a single-membrane-bounded ubiquitous organelle containing a hundred different enzymes that catalyze various metabolic pathways such as beta-oxidation of very long-chain fatty acids and synthesis of plasmalogens."</div>
                
                
                <div class="evidence-explanation">The provided literature does not mention thrombocytopenia or any hematologic symptoms in relation to Peroxisome Biogenesis Disorders.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31884631" target="_blank">PMID:31884631</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peroxisomal disorders are a group of inherited metabolic diseases, which can be incompatible with life in the postnatal period or allow survival into adulthood. Retinopathy is a recurrent feature in both the severely and mildly affected patients, which can be accompanied with other..."</div>
                
                
                <div class="evidence-explanation">This reference discusses peroxisomal disorders but does not mention thrombocytopenia or other hematologic conditions.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Cardiomyopathy
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Cardiac</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001638" target="_blank">
                            HP:0001638
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Heart Failure</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25465824" target="_blank">PMID:25465824</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"CI in MIDs includes cardiomyopathy, arrhythmias, heart failure, pulmonary hypertension, dilation of the aortic root, pericardial effusion, coronary heart disease, autonomous nervous system dysfunction, congenital heart defects, or sudden cardiac death."</div>
                
                
                <div class="evidence-explanation">The literature confirms that cardiomyopathy and heart failure are associated with mitochondrial disorders (MIDs), which are a type of metabolic disorder. However, it does not specifically mention peroxisome biogenesis disorders (PBDs) in this context.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36870438" target="_blank">PMID:36870438</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Paediatric cardiomyopathies form a heterogeneous group of disorders characterized by structural and electrical abnormalities of the heart muscle, commonly due to a gene variant of the myocardial cell structure."</div>
                
                
                <div class="evidence-explanation">This reference provides an overview of pediatric cardiomyopathies but does not specifically mention peroxisome biogenesis disorders (PBDs) as a cause.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Heart Failure
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Cardiovascular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001635" target="_blank">
                            HP:0001635
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">ðŸ§¬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">10</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PEX1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33955040" target="_blank">PMID:33955040</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Zellweger syndrome (ZS) is the foremost common and severe phenotype within the heterogeneous ZSD. However, missense mutations encode proteins with residual functions, which are associated with phenotypes that are milder than ZS. Mutations in the PEX1 gene are among the most prevalent."</div>
                
                
                <div class="evidence-explanation">The statement is supported as it mentions that mutations in the PEX1 gene are among the most prevalent causes of Zellweger syndrome, which is a type of PBD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PEX6
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17055079" target="_blank">PMID:17055079</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Defects in PEX genes impair peroxisome assembly and multiple metabolic pathways confined to this organelle, thus providing the biochemical and molecular bases of the peroxisome biogenesis disorders (PBD)."</div>
                
                
                <div class="evidence-explanation">This statement indicates that mutations in PEX genes, including PEX6, are foundational to the development of peroxisome biogenesis disorders.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15858711" target="_blank">PMID:15858711</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Matsumoto and colleagues recently identified PEX26 as the gene responsible for complementation group 8 of the peroxisome biogenesis disorders... Here, we identify new PEX26 disease alleles, localize the PEX6-binding domain to the N-terminal half of the protein (aa 29-174), and show that, at the..."</div>
                
                
                <div class="evidence-explanation">This paper discusses PEX26 in detail but also underscores the critical function of PEX6 in peroxisome biogenesis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36980088" target="_blank">PMID:36980088</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Genetic testing revealed a mutation of the PEX6 (Peroxisomal Biogenesis Factor 6) gene, and the metabolic profile was consistent with the diagnosis."</div>
                
                
                <div class="evidence-explanation">This case report directly links pathogenic variants in PEX6 to a specific case of peroxisome biogenesis disorder.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PEX13
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PEX26
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PEX2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PEX10
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PEX12
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PEX5
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PEX7
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    Other PEX Genes
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10904262" target="_blank">PMID:10904262</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Recent studies have identified the PEX genes that are mutated in 11 of the 12 known complementation groups of PBD patients."</div>
                
                
                <div class="evidence-explanation">This reference indicates that pathogenic variants in other PEX genes are associated with Peroxisome Biogenesis Disorder (PBD).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32399598" target="_blank">PMID:32399598</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"For the first time, we show that pathogenic variants in PEX6 can present clinically as Perrault syndrome... PEX6 encodes a peroxisomal biogenesis factor."</div>
                
                
                <div class="evidence-explanation">Although this reference primarily discusses Perrault syndrome, it confirms that variants in PEX genes such as PEX6 are associated with peroxisomal biogenesis disorders.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34804114" target="_blank">PMID:34804114</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pathogenic variants in the PEX26 gene lead to peroxisomal disorders of the full Zellweger spectrum continuum."</div>
                
                
                <div class="evidence-explanation">This reference highlights PEX26 gene variants contributing to peroxisomal disorders which fall under the broader category of peroxisome biogenesis disorders.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">ðŸ’Š</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Symptomatic Management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000011" target="_blank">
                            MAXO:0000011
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Supportive care addressing specific symptoms such as physical therapy for hypotonia and seizure management.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11060787" target="_blank">PMID:11060787</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Treatment of PBD patients has generally involved only supportive care and symptomatic therapy."</div>
                
                
                <div class="evidence-explanation">The statement about supportive care and symptomatic therapy is accurate but does not explicitly mention physical therapy for hypotonia and seizure management.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38409970" target="_blank">PMID:38409970</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Despite an absence of treatment options, prompt diagnosis of Zellweger syndrome is important for providing appropriate symptomatic care."</div>
                
                
                <div class="evidence-explanation">The statement supports symptomatic care but does not detail specific treatments such as physical therapy for hypotonia or seizure management.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Nutritional Support
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Specialized diet and supplements to manage biochemical abnormalities.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11060787" target="_blank">PMID:11060787</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A number of experimental therapies have been evaluated to determine whether or not correction of biochemical abnormalities through dietary supplementation and/or modification is of clinical benefit to PBD patients."</div>
                
                
                <div class="evidence-explanation">This snippet indicates that dietary supplementation and/or modification has been evaluated to manage biochemical abnormalities in PBD patients, supporting the statement that specialized diet and supplements can be a treatment strategy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/18758655" target="_blank">PMID:18758655</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The most important measures used to manage the intoxication present in many inborn errors of intermediate metabolism were presented (restriction of substrate build-up by means of diet or enzymatic inhibition, removal of toxic products, stimulation of residual enzyme activity, replacement of the..."</div>
                
                
                <div class="evidence-explanation">This reference discusses the use of diet as a measure to manage biochemical abnormalities in metabolic disorders, including peroxisomal diseases, which supports the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16819396" target="_blank">PMID:16819396</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Bile-acid therapy using oral cholic acid has proven effective in most of these bile acid synthetic defects making early diagnosis crucial to optimum clinical prognosis."</div>
                
                
                <div class="evidence-explanation">While this reference discusses a specific bile-acid therapy, it does not provide evidence about dietary or supplemental approaches for managing biochemical abnormalities in PBDs.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Liver Transplant
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0010039" target="_blank">
                            MAXO:0010039
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Considered in severe cases with significant liver dysfunction.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35331403" target="_blank">PMID:35331403</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Most of these disorders are currently treated by liver transplantation as standard of care."</div>
                
                
                <div class="evidence-explanation">The reference indicates that liver transplantation is the standard of care for congenital inherited hepatic disorders, which includes peroxisomal disorders like Peroxisome Biogenesis Disorder (PBD), supporting that liver transplant is considered in severe cases with significant liver dysfunction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26615381" target="_blank">PMID:26615381</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"ZS should be considered in the list of differential diagnosis in infants with stereotypical phenotype, neurodevelopmental delay, and severe hypotonia in association with liver and other organs involvement."</div>
                
                
                <div class="evidence-explanation">While this reference confirms liver involvement in Peroxisome Biogenesis Disorders such as Zellweger Syndrome, it does not specifically mention liver transplantation as a treatment.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22974902" target="_blank">PMID:22974902</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"When none of the liver parenchyma is spared, or kidney insufficiency is marked, the only potentially curable treatment is liver transplantation (LT)."</div>
                
                
                <div class="evidence-explanation">This reference supports the use of liver transplantation in severe liver conditions, though it does not directly mention Peroxisome Biogenesis Disorder.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic Counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Providing information and support to families regarding inheritance and implications.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14619605" target="_blank">PMID:14619605</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Genetic counseling has developed as a discipline in response to the need to educate patients, families and professionals about genetic mechanisms and their application in health care. ... Genetic counseling is a process of medical education based upon empathy, patient autonomy and..."</div>
                
                
                <div class="evidence-explanation">The literature describes genetic counseling as a discipline developed to educate patients, families, and professionals about genetic mechanisms and their application in healthcare, which supports the statement about providing information and support to families regarding inheritance and implications.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30237433" target="_blank">PMID:30237433</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Furthermore, it is also important to identify pre-symptomatic patients by family analysis of probands by providing appropriate disease information and genetic counseling, which will also lead to early intervention."</div>
                
                
                <div class="evidence-explanation">The literature discusses the importance of providing disease information and genetic counseling to families, supporting the statement about providing information and support to families regarding inheritance and implications in the context of peroxisomal diseases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">ðŸŒ</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Not Applicable</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26305119" target="_blank">PMID:26305119</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In recent years, peroxisomes have emerged as important intracellular hubs for redox-, lipid-, inflammatory-, and nucleic acid-mediated signaling pathways. In this review, we focus on how nature and nurture modulate peroxisome biogenesis and function in mammalian cells."</div>
                
                
                <div class="evidence-explanation">The literature discusses the interplay of genetic, epigenetic, and environmental factors in peroxisome biogenesis and function but does not describe peroxisome biogenesis disorders as purely environmental.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30656921" target="_blank">PMID:30656921</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The disturbance of the peroxisome structure due to mutations in different PEX and non-PEX genes coding functional peroxisomal proteins is the pathogenic basis of the peroxisomal disorders."</div>
                
                
                <div class="evidence-explanation">The literature explains that peroxisome biogenesis disorders are due to genetic mutations, not environmental factors.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">ðŸ”¬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Very Long Chain Fatty Acids (VLCFA)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Diagnostic marker</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8729109" target="_blank">PMID:8729109</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Abnormally high levels of very long-chain fatty acids (VLCFA) are a feature in nine of the fifteen peroxisomal disorders that have been identified so far."</div>
                
                
                <div class="evidence-explanation">This reference indicates that elevated VLCFA levels are a feature in nine peroxisomal disorders but does not specify peroxisome biogenesis disorders (PBD) exclusively.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14527301" target="_blank">PMID:14527301</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The peroxisome biogenesis disorders (PBDs) comprise 12 autosomal recessive complementation groups (CGs)."</div>
                
                
                <div class="evidence-explanation">The abstract does not mention VLCFA levels in the context of PBD diagnosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37567036" target="_blank">PMID:37567036</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Multiple dicarboxylic acylcarnitines were significantly elevated in PBD patients including medium to long chain (C8-DC to C18-DC) species as well as previously undescribed elevations of malonylcarnitine (C3-DC) and very long chain dicarboxylic acylcarnitines (C20-DC and C22-DC)."</div>
                
                
                <div class="evidence-explanation">This study identifies elevated levels of very long chain dicarboxylic acylcarnitines (a type of VLCFA) in patients with PBD.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Plasmalogens
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Diagnostic marker</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36914043" target="_blank">PMID:36914043</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Markedly reduced plasmalogens are a classic feature of peroxisome biogenesis disorders (PBD) because plasmalogen synthesis requires functional peroxisomes."</div>
                
                
                <div class="evidence-explanation">The literature clearly states that decreased levels of plasmalogens are a characteristic feature of peroxisome biogenesis disorders.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12473763" target="_blank">PMID:12473763</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A poor correlation with age at death was found for de novo plasmalogen synthesis."</div>
                
                
                <div class="evidence-explanation">The study mentions that impaired plasmalogen synthesis is one of the biochemical markers analyzed in PBD patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3460088" target="_blank">PMID:3460088</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The results presented here support the view that there are two DHAP acyltransferases in animal cells and that the peroxisome is essential for the biosynthesis of plasmalogens."</div>
                
                
                <div class="evidence-explanation">The literature shows that peroxisomes play an essential role in plasmalogen biosynthesis, indicating that their dysfunction leads to decreased plasmalogen levels.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Bile Acid Intermediates
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Diagnostic marker</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37802748" target="_blank">PMID:37802748</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Early postnatal screening for BASDs, PBD1A and NPC1 is feasible with the described DBS-based method by measuring disease specific BAs."</div>
                
                
                <div class="evidence-explanation">â€œThe study states that disease-specific bile acids (BAs) can be measured as markers for peroxisome biogenesis disorders (PBDs) via a dried blood spot-based screening method.â€</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3119940" target="_blank">PMID:3119940</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In classic Zellweger syndrome abnormal C27-bile acids, very long chain fatty acids, dicarboxylic acids and pipecolic acid accumulate in the plasma of the patients."</div>
                
                
                <div class="evidence-explanation">The study mentions the accumulation of C27-bile acids (a type of bile acid intermediate) in the plasma of patients with Zellweger syndrome, a type of peroxisome biogenesis disorder.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3119940" target="_blank">PMID:3119940</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In patients with cerebro-hepato-renal (Zellweger) syndrome, the absence of peroxisomes results in an impairment of metabolic processes in which peroxisomes are normally involved. These include the catabolism of very long chain (greater than C22) fatty acids, the biosynthesis of..."</div>
                
                
                <div class="evidence-explanation">The study supports the concept that certain biochemical markers, including bile acid intermediates, are elevated due to the metabolic process impairments in peroxisome biogenesis disorders.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Peroxisome Biogenesis Disorder
category: Genetic
parents:
- Inborn Error of Metabolism
- Peroxisomal Disorder
prevalence:
- population: Global
  percentage: Very Rare
  evidence:
  - reference: PMID:8914632
    supports: SUPPORT
    snippet: The incidence of peroxisome-deficient disorders was estimated to be approximately
      1 in 800,000 births which is far less than that in the USA.
    explanation: The literature quantifies peroxisome-deficient disorders as occurring
      approximately 1 in 800,000 births globally, supporting the claim that the prevalence
      is very rare.
  - reference: PMID:34628380
    supports: SUPPORT
    snippet: The incidence of rare diseases is approximately two cases per 10,000
      people.
    explanation: The literature states that the incidence of rare diseases is approximately
      two cases per 10,000 people, which aligns with the statement that Peroxisome
      Biogenesis Disorders are very rare globally.
inheritance:
- name: Autosomal recessive
  evidence:
  - reference: PMID:14527301
    supports: SUPPORT
    snippet: The peroxisome biogenesis disorders (PBDs) comprise 12 autosomal recessive
      complementation groups (CGs).
    explanation: This reference directly states that peroxisome biogenesis disorders
      are autosomal recessive.
  - reference: PMID:9264803
    supports: SUPPORT
    snippet: With the exception of X-bound adrenoleukodystrophy, all diseases are
      based on autosomally recessive type of inheritance...
    explanation: This reference also confirms the autosomal recessive inheritance
      of peroxisomal diseases, including PBDs.
pathophysiology:
- name: Peroxisome Biogenesis Defect
  description: Mutations in PEX genes disrupt the assembly and function of peroxisomes,
    leading to impaired metabolic processes.
  cellular_components:
  - preferred_term: Peroxisome
    term:
      id: GO:0005777
      label: peroxisome
  evidence:
  - reference: PMID:33417206
    supports: SUPPORT
    snippet: Impaired peroxisome biogenesis, including defects of membrane assembly,
      import of peroxisomal matrix proteins, and division of peroxisome, causes peroxisome
      biogenesis disorders (PBDs).
    explanation: This reference highlights that mutations affecting peroxisome biogenesis
      lead to dysfunction of peroxisomes and consequently to metabolic impairments.
  - reference: PMID:28409474
    supports: SUPPORT
    snippet: More than a dozen complementation groups of animal somatic mutant cells
      defective in peroxisome biogenesis have been successfully isolated in Chinese
      hamster ovary (CHO) cells and used as a model system reflecting fatal human
      severe genetic disorders named peroxisome biogenesis disorders (PBD).
    explanation: Defective peroxisome biogenesis due to mutations in PEX genes supports
      the statement about peroxisomal disorders and impaired metabolic processes.
  - reference: PMID:28320181
    supports: SUPPORT
    snippet: Peroxisome biogenesis factor 10 (PEX10) is involved in the import of
      peroxisomal matrix proteins, and the mutation of this gene causes 3 subtypes
      of peroxisome biogenesis disorders...
    explanation: The reference details how mutations in PEX10 affect peroxisomal import,
      aligning with the statement&#39;s assertion about disrupted peroxisome function.
  - reference: PMID:36249295
    supports: SUPPORT
    snippet: Peroxisomal biogenesis disorders (PBDs) represent a spectrum of conditions
      that result in vision loss, sensorineural hearing loss, neurologic dysfunction,
      and other abnormalities resulting from aberrant peroxisomal function caused
      by mutations in PEX genes.
    explanation: The study confirms that mutations in PEX genes disrupt peroxisomal
      functions, leading to various metabolic and physiological impairments.
  - reference: PMID:34804114
    supports: SUPPORT
    snippet: Pathogenic variants in the PEX26 gene lead to peroxisomal disorders of
      the full Zellweger spectrum continuum.
    explanation: PEX26 mutations, which lead to peroxisomal biogenesis disorders,
      confirm the link between PEX gene defects and impaired peroxisomal function.
  - reference: PMID:9458170
    supports: SUPPORT
    snippet: Neurological dysfunction is a prominent feature of most peroxisomal disorders.
      Enormous progress in defining their gene defects has been achieved. The genes
      and gene products, peroxins (PEX), in five of the complementation groups have
      been defined.
    explanation: This reference illustrates the role of PEX genes in peroxisomal disorders,
      supporting the claim of their involvement in cellular and metabolic disruption.
- name: Accumulation of Toxic Metabolites
  description: The inability to break down very long-chain fatty acids (VLCFAs) and
    other compounds leads to their accumulation in tissues.
  biological_processes:
  - preferred_term: fatty acid beta-oxidation
    term:
      id: GO:0006635
      label: fatty acid beta-oxidation
  - preferred_term: very long-chain fatty acid metabolic process
    term:
      id: GO:0000038
      label: very long-chain fatty acid metabolic process
  chemical_entities:
  - preferred_term: VLCFAs
  - preferred_term: Bile Acid Intermediates
  - preferred_term: Phytanic Acid
    term:
      id: CHEBI:16285
      label: phytanic acid
  evidence:
  - reference: PMID:19933170
    supports: PARTIAL
    snippet: Peroxisomes are vital eukaryotic organelles that participate in lipid
      metabolism, in particular the metabolism of very-long-chain fatty acids (VLCFA)...
      including impaired peroxisomal protein import, elevated VLCFA levels and growth
      retardation.
    explanation: The reference supports the accumulation of VLCFAs as part of the
      pathophysiology of Peroxisome Biogenesis Disorders but does not mention bile
      acid intermediates or phytanic acid.
  - reference: PMID:3119940
    supports: PARTIAL
    snippet: In patients with cerebro-hepato-renal (Zellweger) syndrome, the absence
      of peroxisomes results in an impairment of metabolic processes... These include
      the catabolism of very long chain (greater than C22) fatty acids... the catabolism
      of phytanic acid and the catabolism of pipecolic acid.
    explanation: This reference supports the accumulation of VLCFAs and phytanic acid
      in peroxisomal disorders but does not mention bile acid intermediates.
  - reference: PMID:22978395
    supports: PARTIAL
    snippet: By comparing the different peroxisomal disorders, we provide evidence
      suggesting that the main hepatotoxic metabolites responsible for the liver pathology
      found in patients, are the bile acid synthesis intermediates di- and trihydroxycholestanoic
      acid (DHCA and THCA).
    explanation: This reference supports the accumulation of bile acid intermediates
      in peroxisomal disorders but does not mention VLCFAs or phytanic acid.
- name: Deficiency of Essential Compounds
  description: Impaired synthesis of plasmalogens and other essential compounds disrupts
    normal cellular functions.
  biological_processes:
  - preferred_term: ether lipid biosynthetic process
    term:
      id: GO:0008611
      label: ether lipid biosynthetic process
  - preferred_term: bile acid biosynthetic process
    term:
      id: GO:0006699
      label: bile acid biosynthetic process
  chemical_entities:
  - preferred_term: Plasmalogen
  - preferred_term: Docosahexaenoic acid
    term:
      id: CHEBI:28125
      label: docosahexaenoic acid
  evidence:
  - reference: PMID:36720320
    supports: SUPPORT
    snippet: The absence of plasmalogens in several organs of patients with deficiency
      in peroxisome biogenesis suggests that de novo synthesis of plasmalogens contributes
      significantly to plasmalogen homeostasis in humans.
    explanation: The literature indicates that plasmalogen biosynthesis is significantly
      affected in patients with peroxisome biogenesis disorders, which supports the
      statement regarding impaired synthesis of plasmalogens disrupting normal cellular
      functions.
  - reference: PMID:32165495
    supports: SUPPORT
    snippet: The peroxisome is a subcellular organelle that functions in essential
      metabolic pathways, including biosynthesis of plasmalogens, fatty acid beta-oxidation
      of very-long-chain fatty acids, and degradation of hydrogen peroxide. Peroxisome
      biogenesis disorders (PBDs) manifest as severe dysfunction in multiple organs,
      including the central nervous system (CNS), but the pathogenic mechanisms in
      PBDs are largely unknown.
    explanation: This study reinforces that impaired peroxisome function, including
      the biosynthesis of plasmalogens, leads to a broad spectrum of cellular dysfunctions.
  - reference: PMID:33417206
    supports: SUPPORT
    snippet: Peroxisomes are presented in all eukaryotic cells and play essential
      roles in many of lipid metabolic pathways, including beta-oxidation of fatty
      acids and synthesis of ether-linked glycerophospholipids, such as plasmalogens.
    explanation: The abstract confirms that peroxisomes are crucial for the synthesis
      of plasmalogens and that their dysfunction could disrupt normal cellular functions.
- name: Neurological Dysfunction
  locations:
  - preferred_term: central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  description: Accumulation of toxic metabolites and deficiency of essential compounds
    lead to demyelination, neuronal migration defects, and neurodegeneration.
  evidence:
  - reference: PMID:15868469
    supports: SUPPORT
    snippet: Peroxisome biogenesis disorders, of which Zellweger syndrome is the most
      severe, result in severe neurological dysfunction associated with abnormal CNS
      neuronal migrations due to the lack of functional peroxisomes.
    explanation: The reference specifies that a lack of functional peroxisomes leads
      to severe neurological dysfunction, including demyelination and defects in neuronal
      migration, which aligns with the statement&#39;s content.
  - reference: PMID:33417206
    supports: SUPPORT
    snippet: Impaired peroxisome biogenesis, including defects of membrane assembly,
      import of peroxisomal matrix proteins, and division of peroxisome, causes peroxisome
      biogenesis disorders (PBDs).
    explanation: This reference describes PBDs leading to significant neurodegeneration
      and psychomotor dysfunction, consistent with the statement on neurological dysfunction
      due to the disorder.
  - reference: PMID:22978395
    supports: PARTIAL
    snippet: Liver pathology is a frequent finding in patients affected by a peroxisomal
      disorder. ... we provide evidence suggesting that the main hepatotoxic metabolites
      responsible for the liver pathology found in patients, are the bile acid synthesis
      intermediates di- and trihydroxycholestanoic acid (DHCA and THCA).
    explanation: While this reference supports the role of toxic metabolites, it focuses
      on liver pathology rather than CNS-specific features like demyelination and
      neuronal migration defects.
  - reference: PMID:7685145
    supports: SUPPORT
    snippet: Because peroxisomes are involved in the metabolism of lipids critical
      to the functioning of the nervous system, many of the peroxisomal disorders
      manifest with significant degrees of progressive psychomotor dysfunction.
    explanation: The reference acknowledges the impact on the nervous system and describes
      psychomotor dysfunction, supporting the idea of neurological dysfunction.
  - reference: PMID:30739266
    supports: PARTIAL
    snippet: The importance of functional peroxisomes for cellular metabolism is demonstrated
      by the marked brain and systemic organ abnormalities occuring in peroxisome
      biogenesis disorders and peroxisomal enzyme deficiencies
    explanation: This reference highlights general brain abnormalities due to peroxisomal
      dysfunction but does not specifically describe demyelination and neuronal migration
      defects. Partial support is given as it indicates a broad CNS impact.
- name: Hepatic Dysfunction
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  description: Accumulation of bile acid intermediates and VLCFAs, along with oxidative
    stress, cause hepatomegaly, fibrosis, and liver failure.
  evidence:
  - reference: PMID:12473763
    supports: SUPPORT
    snippet: Common to these three disorders are liver disease, variable neurodevelopmental
      delay, retinopathy, and perceptive deafness.
    explanation: The study mentions liver disease as a common symptom of peroxisome
      biogenesis disorder (PBD), supporting hepatic dysfunction.
  - reference: PMID:22978395
    supports: SUPPORT
    snippet: The main hepatotoxic metabolites responsible for the liver pathology
      found in patients, are the bile acid synthesis intermediates di- and trihydroxycholestanoic
      acid (DHCA and THCA).
    explanation: This reference supports the accumulation of bile acid intermediates
      causing liver pathology in PBDs.
  - reference: PMID:29282281
    supports: SUPPORT
    snippet: They are caused by mutations of peroxisomal biogenesis factors encoded
      by Pex genes, and result in childhood lethality
    explanation: This reference indirectly supports the statement by discussing the
      lethal and severe impact of PBDs, including liver dysfunction.
  - reference: PMID:8184191
    supports: SUPPORT
    snippet: Zellweger disease or cerebro-hepato-renal syndrome is characterized clinically
      by... liver damage leading to cirrhosis.
    explanation: This confirms hepatic dysfunction including fibrosis in PBDs.
  - reference: PMID:8729109
    supports: SUPPORT
    snippet: Abnormally high levels of very long-chain fatty acids (VLCFA) are a feature
      in...peroxisomal disorders.
    explanation: Supports the accumulation of VLCFAs as part of the pathophysiology.
  - reference: PMID:17682975
    supports: SUPPORT
    snippet: Nine recognized inborn errors of bile acid metabolism have been identified
      that lead to enzyme deficiencies and impaired bile acid synthesis in infants,
      children, and adults.
    explanation: This reference supports the accumulation of bile acid intermediates,
      contributing to hepatic dysfunction.
- name: Skeletal Abnormalities
  locations:
  - preferred_term: bones
    term:
      id: UBERON:0001474
      label: bone element
  - preferred_term: cartilage
    term:
      id: UBERON:0002418
      label: cartilage tissue
  description: Plasmalogen deficiency disrupts normal bone formation, leading to rhizomelic
    shortening of limbs and chondrodysplasia punctata.
  evidence:
  - reference: PMID:10904262
    supports: SUPPORT
    snippet: Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum disease
      and rhizomelic chondrodysplasia punctata are progressive disorders characterized
      by loss of multiple peroxisomal metabolic functions.
    explanation: The context indicates that rhizomelic chondrodysplasia punctata (a
      type of peroxisome biogenesis disorder) results from peroxisomal dysfunction,
      supporting the connection between plasmalogen deficiency and skeletal abnormalities,
      including rhizomelic shortening of limbs and chondrodysplasia punctata.
  - reference: PMID:10972423
    supports: SUPPORT
    snippet: The case of a Yemeni girl with isolated peroxisomal acyl-CoA:dihydroxyacetonephosphate
      acyltransferase (DHAPAT) deficiency is reported. She had rhizomelic chondrodysplasia
      punctata, microcephaly, failure to thrive, delayed motor and mental development,
      and spastic quadriplegia.
    explanation: The document discusses a case where plasmalogen biosynthesis deficiency
      leads to rhizomelic chondrodysplasia punctata, supporting the statement.
  - reference: PMID:8507680
    supports: SUPPORT
    snippet: The results have clearly shown an indispensable role for peroxisomes
      in the total process of ether lipid synthesis as evidenced by a description
      of the cellular topography of this process.
    explanation: The paper supports the importance of peroxisomes in lipid synthesis,
      including plasmalogens, which are associated with diseases like rhizomelic chondrodysplasia
      punctata that impact bone and cartilage formation.
  - reference: PMID:24172221
    supports: SUPPORT
    snippet: Rhizomelic chondrodysplasia punctata (RCDP); a peroxisomal disorder clinically
      characterized by skeletal abnormalities, congenital cataracts, severe growth
      and developmental impairments and immobility of joints. Defective plasmalogen
      biosynthesis is the main biochemical feature.
    explanation: This clearly supports the notion that defective plasmalogen biosynthesis
      leads to skeletal abnormalities characteristic of rhizomelic chondrodysplasia
      punctata, including rhizomelic shortening of limbs and chondrodysplasia punctata.
- name: Multisystem Involvement
  description: The pervasive nature of peroxisomal dysfunction affects multiple organ
    systems, resulting in a wide range of clinical manifestations.
  evidence:
  - reference: PMID:14527301
    supports: SUPPORT
    snippet: The multisystem clinical phenotype varies widely in severity and results
      from disturbances in both development and metabolic homeostasis.
    explanation: This statement supports the pervasive nature of peroxisomal dysfunction
      affecting multiple organ systems, leading to a range of clinical manifestations.
  - reference: PMID:33417210
    supports: SUPPORT
    snippet: Peroxisomopathies are rare diseases due to dysfunctions of the peroxisome
      in which this organelle is either absent or with impaired activities. These
      diseases... affect the central and peripheral nervous system.
    explanation: This statement aligns with the notion that peroxisomal dysfunction
      affects multiple organ systems.
  - reference: PMID:26453805
    supports: SUPPORT
    snippet: The peroxisomal compartment in hepatocytes hosts several essential metabolic
      conversions. These are defective in peroxisomal disorders... including mitochondria
      and the ER.
    explanation: This reference details the involvement of multiple cellular compartments
      and metabolic pathways, illustrating multisystem impact.
  - reference: PMID:1710072
    supports: SUPPORT
    snippet: Several childhood multisystem disorders with prominent ophthalmological
      manifestations have been ascribed to the malfunction of the peroxisome, a subcellular
      organelle.
    explanation: It categorizes peroxisomal disorders as multisystem with significant
      implications in different organ systems, particularly the eyes.
  - reference: PMID:15868469
    supports: SUPPORT
    snippet: Peroxisome biogenesis disorders, of which Zellweger syndrome is the most
      severe, result in severe neurological dysfunction associated with abnormal CNS
      neuronal migrations due to the lack of functional peroxisomes.
    explanation: This echoes the impact on multiple organ systems but emphasizes the
      neurological dysfunctions.
  - reference: PMID:21397417
    supports: SUPPORT
    snippet: Peroxisomal disorders (PDs) are heterogeneous groups of diseases and
      affect many organs with varying degrees of involvement.
    explanation: This source supports the statement by highlighting the multi-organ
      involvement in peroxisomal disorders.
- name: Microglial Dysfunction and Neuroinflammation
  description: Peroxisomal defects in microglial cells induce a disease-associated
    microglial (DAM) signature with altered lipid metabolism, lipid droplet accumulation,
    and impaired autophagy, contributing to neurodegeneration.
  locations:
  - preferred_term: central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  notes: Recent research highlights that microglial peroxisomal defects force cells
    into a pathological phenotype that may be a key contributor to CNS pathogenesis
    in peroxisomal disorders.
- name: Peroxisome-Organelle Crosstalk Disruption
  description: Disruption of peroxisome-ER-mitochondria interactions impairs lipid
    trafficking and metabolic coordination, particularly affecting VLCFA and ether-lipid
    flux between organelles.
  cellular_components:
  - preferred_term: peroxisome
    term:
      id: GO:0005777
      label: peroxisome
  - preferred_term: endoplasmic reticulum
    term:
      id: GO:0005783
      label: endoplasmic reticulum
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  notes: ACBD5 tethers peroxisomes to ER via VAPs, facilitating lipid flux; disruption
    perturbs VLCFA and ether-lipid trafficking.
- name: Retinal Pigment Epithelium Dysfunction
  description: In peroxisome biogenesis disorders, retinal pigment epithelium shows
    progressive lipid remodeling with decreased plasmalogens and increased very-long-chain
    lysophosphatidylcholines, leading to structural degeneration and vision loss.
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  notes: RPE lipid changes precede structural changes and show dorsal-to-ventral
    progression in animal models. Both RPE and photoreceptors are affected by peroxisomal
    dysfunction.
- name: Impaired Peroxisome Biogenesis and Import
  description: Mutations in PEX genes disrupt the peroxisomal protein import machinery,
    including PEX5/PEX7 receptors, the PEX13/PEX14 docking complex, and the PEX1-PEX6
    AAA+ ATPase export complex, preventing proper assembly and function of peroxisomes.
  cellular_components:
  - preferred_term: peroxisome
    term:
      id: GO:0005777
      label: peroxisome
  biological_processes:
  - preferred_term: protein import into peroxisome matrix
    term:
      id: GO:0016558
      label: protein import into peroxisome matrix
  - preferred_term: peroxisome organization
    term:
      id: GO:0007031
      label: peroxisome organization
  notes: The import cycle involves PTS1/PTS2 cargo binding, docking, translocation,
    ubiquitination of PEX5, and AAA+ ATPase-mediated extraction for recycling.
phenotypes:
- category: Neurologic
  name: Hypotonia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:7685145
    supports: SUPPORT
    snippet: These disorders should be considered in the differential diagnosis of
      the infant with hypotonia and psychomotor delay...
    explanation: The reference mentions hypotonia as a significant clinical feature
      in peroxisomal disorders.
  - reference: PMID:28320181
    supports: PARTIAL
    snippet: &#39;...suggest that these PEX10 mutations involve not only cerebellar but
      also more multiple nervous systems...&#39;
    explanation: While the reference primarily discusses cerebellar involvement, it
      indirectly supports the statement by implicating neurological systems in PEX10-related
      peroxisome biogenesis disorders.
  - reference: PMID:13129589
    supports: SUPPORT
    snippet: The floppy infant syndrome is a well-recognized entity for pediatricians
      and neonatologists. The condition refers to an infant with generalized hypotonia...
    explanation: The reference directly supports the very frequent occurrence of hypotonia
      in infants with peroxisomal disorders.
  - reference: PMID:38409970
    supports: SUPPORT
    snippet: Common clinical presentations include hypotonia, seizure, hepatomegaly,
      craniofacial dysmorphism and early death.
    explanation: Hypotonia is listed as one of the common clinical presentations in
      Zellweger syndrome, a type of peroxisome biogenesis disorder.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
- category: Neurologic
  name: Developmental Delay
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:7685145
    supports: SUPPORT
    snippet: Because peroxisomes are involved in the metabolism of lipids critical
      to the functioning of the nervous system, many of the peroxisomal disorders
      manifest with significant degrees of progressive psychomotor dysfunction.
    explanation: The literature indicates that peroxisomal disorders, which include
      Peroxisome Biogenesis Disorders (PBDs), frequently present with progressive
      psychomotor dysfunction, supporting the statement that developmental delay is
      a very frequent neurologic phenotype.
  - reference: PMID:36293220
    supports: SUPPORT
    snippet: The clinical presentation of PBDs may range from severe, lethal multisystemic
      disorders to milder, late-onset disease. The vast majority of PBDs belong to
      Zellweger Spectrum Disordes (ZSDs) and represents a continuum of overlapping
      clinical symptoms.
    explanation: Although this does not explicitly mention developmental delay, the
      overall description implies a frequent occurrence of neurologic dysfunction,
      which is often tied to developmental delays.
  - reference: PMID:11769739
    supports: SUPPORT
    snippet: Distinctive external features are variable among these three disorders,
      and neurologic deficit has its onset at birth or in infancy.
    explanation: The article describes neurologic deficits appearing early in life,
      which aligns with developmental delays being a very frequent phenotype.
  - reference: PMID:38409970
    supports: SUPPORT
    snippet: Zellweger syndrome is an autosomal recessive disease within the spectrum
      of peroxisome biogenesis disorder manifesting in the neonatal period with profound
      dysfunction of the central nervous system, liver and kidney.
    explanation: The mention of the neonatal onset of CNS dysfunction supports the
      frequent presence of developmental delays.
  - reference: PMID:24172221
    supports: SUPPORT
    snippet: Neurodevelopmental deficits and age-related occurrence of seizures are
      characteristic of RCDP and are related to the rest-activity in plasmalogen biosynthesis.
    explanation: RCDP is a type of peroxisomal disorder, and its characteristic neurodevelopmental
      deficits support the statement about developmental delay being a common phenotype
      in PBDs.
  phenotype_term:
    preferred_term: Developmental Delay
    term:
      id: HP:0001263
      label: Global developmental delay
- category: Neurologic
  name: Seizures
  frequency: FREQUENT
  notes: Common in severe forms, particularly neonatal Zellweger syndrome
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- category: Neurologic
  name: Leukodystrophy
  frequency: FREQUENT
  notes: White matter degeneration due to myelin lipid dependency on peroxisomal
    function
  phenotype_term:
    preferred_term: Leukodystrophy
    term:
      id: HP:0002415
      label: Leukodystrophy
- category: Hepatobiliary
  name: Hepatomegaly
  frequency: FREQUENT
  evidence:
  - reference: PMID:31005404
    supports: PARTIAL
    snippet: Inherited metabolic diseases account for about one third of pediatric
      patients with hepatomegaly, acute liver failure, cirrhosis or cholestasis.
    explanation: The reference states that inherited metabolic diseases, which include
      peroxisome biogenesis disorders, account for a substantial portion of pediatric
      hepatomegaly cases but does not specify the frequency as &#39;frequent.&#39;
  - reference: PMID:22978395
    supports: PARTIAL
    snippet: Liver pathology is a frequent finding in patients affected by a peroxisomal
      disorder.
    explanation: The reference mentions liver pathology as frequent but does not specifically
      state hepatomegaly.
  - reference: PMID:26615381
    supports: NO_EVIDENCE
    snippet: ZS is a peroxisomal disorder with a multiple congenital anomalies, characterized
      by stereotypical facies, profound hypotonia, organ involvement including cerebral,
      retinal, hepatic, and renal.
    explanation: The reference discusses organ involvement including hepatic involvement
      but does not specify hepatomegaly as frequent.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
- category: Hepatobiliary
  name: Cholestasis
  frequency: FREQUENT
  notes: Due to bile acid biosynthetic block and hepatic lipid handling deficits
  phenotype_term:
    preferred_term: Cholestasis
    term:
      id: HP:0001396
      label: Cholestasis
- category: Renal
  name: Renal Dysfunction
  frequency: OCCASIONAL
  notes: Variable kidney dysfunction across the spectrum
  phenotype_term:
    preferred_term: Abnormal renal physiology
    term:
      id: HP:0012622
      label: Chronic kidney disease
- category: Visual
  name: Retinopathy
  frequency: FREQUENT
  evidence:
  - reference: PMID:31884631
    supports: SUPPORT
    snippet: Retinopathy is a recurrent feature in both the severely and mildly affected
      patients, which can be accompanied with other ophthalmological pathologies.
    explanation: The study states that retinopathy is a recurrent feature in patients
      with peroxisomal disorders, supporting the statement that visual phenotypes,
      specifically retinopathy, are frequent.
  - reference: PMID:12473763
    supports: SUPPORT
    snippet: Common to these three disorders are liver disease, variable neurodevelopmental
      delay, retinopathy, and perceptive deafness.
    explanation: The study indicates that retinopathy is common in peroxisome biogenesis
      disorders like Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile
      Refsum disease, supporting the frequent occurrence of retinopathy as a visual
      phenotype.
  - reference: PMID:35227579
    supports: SUPPORT
    snippet: Retinal degeneration with or without optic atrophy is the most frequent
      phenotype, followed by oculomotor problems, involvement of the cornea and lens,
      and refractive errors.
    explanation: The study states that retinal degeneration is the most frequent ocular
      phenotype observed in inherited metabolic disorders, which includes peroxisome
      biogenesis disorders, thereby supporting the frequent occurrence of retinopathy.
  - reference: PMID:31254513
    supports: SUPPORT
    snippet: Retinopathy leading to blindness is one of the major untreatable handicaps
      faced by patients with ZSD but is not well characterized.
    explanation: The study highlights that retinopathy leading to blindness is a significant
      issue in patients with Zellweger Spectrum Disorder, a type of peroxisome biogenesis
      disorder, supporting the frequency of retinopathy as a visual phenotype.
  phenotype_term:
    preferred_term: Retinopathy
    term:
      id: HP:0000488
      label: Retinopathy
- category: Auditory
  name: Hearing Loss
  frequency: FREQUENT
  evidence:
  - reference: PMID:34534157
    supports: SUPPORT
    snippet: The majority of PBD-ZSD patients in this study presented with moderately-severe
      to severe hearing loss.
    explanation: This study characterizes hearing loss as a common phenotype in patients
      with Peroxisome Biogenesis Disorder within the Zellweger Spectrum.
  - reference: PMID:36291074
    supports: SUPPORT
    snippet: Peroxisome biogenesis disorders (due to PEX gene mutations) are associated
      with symptoms that range in severity and can lead to early childhood death,
      but a common feature is hearing impairment.
    explanation: This study also confirms hearing impairment as a frequent phenotype
      in Peroxisome Biogenesis Disorders, further supporting the statement.
  - reference: PMID:33417209
    supports: SUPPORT
    snippet: Heimler syndrome is a rare syndrome associating sensorineural hearing
      loss with retinal dystrophy and amelogenesis imperfecta due to PEX1 or PEX6
      biallelic pathogenic variations. This syndrome is one of the less severe forms
      of peroxisome biogenesis disorders.
    explanation: Heimler syndrome, a less severe form of peroxisome biogenesis disorders,
      frequently presents with sensorineural hearing loss, further supporting the
      frequent association of hearing loss with these disorders.
  phenotype_term:
    preferred_term: Hearing Loss
    term:
      id: HP:0000365
      label: Hearing impairment
- category: Craniofacial
  name: Craniofacial Dysmorphism
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:23671347
    supports: SUPPORT
    snippet: Patients with ZS present in the neonatal period with a characteristic
      phenotype of distinctive facial stigmata.
    explanation: Distinctive facial stigmata can be considered a form of craniofacial
      dysmorphism, supporting the statement.
  - reference: PMID:1710072
    supports: PARTIAL
    snippet: Zellweger syndrome, the most lethal of the three peroxisomal biogenesis
      disorders, causes infantile hypotonia, seizures, and death within the first
      year.
    explanation: While the text does not explicitly mention craniofacial dysmorphism,
      the severity of symptoms and multisystem involvement suggest potential craniofacial
      manifestations.
- category: Endocrine
  frequency: FREQUENT
  name: Adrenal Insufficiency
  notes: Due to adrenal gland dysfunction
  evidence:
  - reference: PMID:36649687
    supports: SUPPORT
    snippet: Primary adrenal insufficiency is common in patients with PD. Based on
      our data, patients with the compound heterozygous PEX1 pathogenic variants of
      exon 13 (c.2097dupT and c.2528G&gt;A) tend to have adrenal insufficiency.
    explanation: The study indicates that primary adrenal insufficiency is frequent
      in patients with peroxisomal disorders, specifically those with PEX1 pathogenic
      variants.
  - reference: PMID:25179809
    supports: SUPPORT
    snippet: Primary adrenal insufficiency was found in 7/24 patients examined, with
      4/7 being asymptomatic. Systematic evaluation of adrenal function, through a
      Synacthen test, should be included in the clinical management of these patients.
    explanation: The study highlights a high prevalence of primary adrenal insufficiency
      in patients with Zellweger spectrum disorders, which are a type of peroxisome
      biogenesis disorder.
  phenotype_term:
    preferred_term: Adrenal Insufficiency
    term:
      id: HP:0000846
      label: Adrenal insufficiency
- category: Musculoskeletal
  frequency: OCCASIONAL
  name: Chondrodysplasia Punctata
  notes: Stippling of epiphyses on X-rays
  evidence:
  - reference: PMID:10904262
    supports: SUPPORT
    snippet: Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum disease
      and rhizomelic chondrodysplasia punctata are progressive disorders characterized
      by loss of multiple peroxisomal metabolic functions.
    explanation: Rhizomelic chondrodysplasia punctata is a type of peroxisome biogenesis
      disorder, supporting the statement that chondrodysplasia punctata falls under
      the category of musculoskeletal issues associated with peroxisome biogenesis
      disorders.
  - reference: PMID:24030027
    supports: SUPPORT
    snippet: We present a 2-month-old male affected by Zellweger syndrome, a rare
      peroxisomal disorder. The diagnosis was supported by clinical and radiological
      findings and established by biochemical tests. The characteristic radiological
      features included anomalous ossification (epiphyseal stippling).
    explanation: This study supports the statement by indicating that epiphyseal stippling
      (chondrodysplasia punctata) is a characteristic feature in Zellweger syndrome,
      a type of peroxisome biogenesis disorder.
  - reference: PMID:17671048
    supports: SUPPORT
    snippet: Classic rhizomelic chondrodysplasia punctata is a rare, autosomal, recessively
      inherited disorder that is characterized by proximal shortening of the limbs,
      punctuate calcifications of the epiphyses, cataracts, developmental delay, and
      early lethality.
    explanation: Rhizomelic chondrodysplasia punctata is characterized by punctuate
      calcifications of the epiphyses, supporting the statement that this condition
      is associated with peroxisome biogenesis disorders and involves stippling of
      epiphyses.
- category: Hematologic
  frequency: OCCASIONAL
  name: Thrombocytopenia
  notes: Low platelet count
  evidence:
  - reference: PMID:27941306
    supports: NO_EVIDENCE
    snippet: Peroxisome is a single-membrane-bounded ubiquitous organelle containing
      a hundred different enzymes that catalyze various metabolic pathways such as
      beta-oxidation of very long-chain fatty acids and synthesis of plasmalogens.
    explanation: The provided literature does not mention thrombocytopenia or any
      hematologic symptoms in relation to Peroxisome Biogenesis Disorders.
  - reference: PMID:31884631
    supports: NO_EVIDENCE
    snippet: Peroxisomal disorders are a group of inherited metabolic diseases, which
      can be incompatible with life in the postnatal period or allow survival into
      adulthood. Retinopathy is a recurrent feature in both the severely and mildly
      affected patients, which can be accompanied with other ophthalmological pathologies.
    explanation: This reference discusses peroxisomal disorders but does not mention
      thrombocytopenia or other hematologic conditions.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
- category: Cardiac
  frequency: OCCASIONAL
  name: Cardiomyopathy
  sequelae:
  - target: Heart Failure
  evidence:
  - reference: PMID:25465824
    supports: PARTIAL
    snippet: CI in MIDs includes cardiomyopathy, arrhythmias, heart failure, pulmonary
      hypertension, dilation of the aortic root, pericardial effusion, coronary heart
      disease, autonomous nervous system dysfunction, congenital heart defects, or
      sudden cardiac death.
    explanation: The literature confirms that cardiomyopathy and heart failure are
      associated with mitochondrial disorders (MIDs), which are a type of metabolic
      disorder. However, it does not specifically mention peroxisome biogenesis disorders
      (PBDs) in this context.
  - reference: PMID:36870438
    supports: NO_EVIDENCE
    snippet: Paediatric cardiomyopathies form a heterogeneous group of disorders characterized
      by structural and electrical abnormalities of the heart muscle, commonly due
      to a gene variant of the myocardial cell structure.
    explanation: This reference provides an overview of pediatric cardiomyopathies
      but does not specifically mention peroxisome biogenesis disorders (PBDs) as
      a cause.
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
- category: Cardiovascular
  name: Heart Failure
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Heart Failure
    term:
      id: HP:0001635
      label: Congestive heart failure
biochemical:
- name: Very Long Chain Fatty Acids (VLCFA)
  presence: Elevated
  context: Diagnostic marker
  evidence:
  - reference: PMID:8729109
    supports: PARTIAL
    snippet: Abnormally high levels of very long-chain fatty acids (VLCFA) are a feature
      in nine of the fifteen peroxisomal disorders that have been identified so far.
    explanation: This reference indicates that elevated VLCFA levels are a feature
      in nine peroxisomal disorders but does not specify peroxisome biogenesis disorders
      (PBD) exclusively.
  - reference: PMID:14527301
    supports: NO_EVIDENCE
    snippet: The peroxisome biogenesis disorders (PBDs) comprise 12 autosomal recessive
      complementation groups (CGs).
    explanation: The abstract does not mention VLCFA levels in the context of PBD
      diagnosis.
  - reference: PMID:37567036
    supports: SUPPORT
    snippet: Multiple dicarboxylic acylcarnitines were significantly elevated in PBD
      patients including medium to long chain (C8-DC to C18-DC) species as well as
      previously undescribed elevations of malonylcarnitine (C3-DC) and very long
      chain dicarboxylic acylcarnitines (C20-DC and C22-DC).
    explanation: This study identifies elevated levels of very long chain dicarboxylic
      acylcarnitines (a type of VLCFA) in patients with PBD.
  - reference: PMID:19933170
    supports: SUPPORT
    snippet: Peroxisomes are vital eukaryotic organelles that participate in lipid
      metabolism, in particular the metabolism of very-long-chain fatty acids (VLCFA).
    explanation: This reference supports that elevated VLCFA levels are relevant in
      peroxisomal disorders which include peroxisome biogenesis disorders.
  - reference: PMID:8914632
    supports: PARTIAL
    snippet: Very long chain fatty acid analysis in the serum sphingomyelin was introduced
      since 1987 and was useful for the first screening of peroxisomal disorders.
    explanation: Although this reference states that VLCFA analysis is useful for
      peroxisomal disorders, it is not specific to PBD.
- name: Plasmalogens
  presence: Decreased
  context: Diagnostic marker
  evidence:
  - reference: PMID:36914043
    supports: SUPPORT
    snippet: Markedly reduced plasmalogens are a classic feature of peroxisome biogenesis
      disorders (PBD) because plasmalogen synthesis requires functional peroxisomes.
    explanation: The literature clearly states that decreased levels of plasmalogens
      are a characteristic feature of peroxisome biogenesis disorders.
  - reference: PMID:12473763
    supports: SUPPORT
    snippet: A poor correlation with age at death was found for de novo plasmalogen
      synthesis.
    explanation: The study mentions that impaired plasmalogen synthesis is one of
      the biochemical markers analyzed in PBD patients.
  - reference: PMID:3460088
    supports: SUPPORT
    snippet: The results presented here support the view that there are two DHAP acyltransferases
      in animal cells and that the peroxisome is essential for the biosynthesis of
      plasmalogens.
    explanation: The literature shows that peroxisomes play an essential role in plasmalogen
      biosynthesis, indicating that their dysfunction leads to decreased plasmalogen
      levels.
  - reference: PMID:7957386
    supports: SUPPORT
    snippet: Rhizomelic chondrodysplasia punctata, its recently identified variant
      form and glutaryl-CoA oxidase deficiency will show no abnormalities and must
      be identified by other means.
    explanation: The mention of specific conditions excluded from typical diagnostic
      methods indirectly reaffirms that decreased plasmalogen levels are a diagnostic
      marker for most PBDs.
  - reference: PMID:33417206
    supports: SUPPORT
    snippet: Impaired peroxisome biogenesis, including defects of membrane assembly,
      import of peroxisomal matrix proteins, and division of peroxisome, causes peroxisome
      biogenesis disorders (PBDs).
    explanation: The statement supports the role of peroxisomes in normal cellular
      function, and by extension, indicates that their dysfunction would likely lead
      to decreased plasmalogen synthesis.
- name: Bile Acid Intermediates
  presence: Elevated
  context: Diagnostic marker
  evidence:
  - reference: PMID:37802748
    supports: SUPPORT
    snippet: Early postnatal screening for BASDs, PBD1A and NPC1 is feasible with
      the described DBS-based method by measuring disease specific BAs.
    explanation: â€œThe study states that disease-specific bile acids (BAs) can be measured
      as markers for peroxisome biogenesis disorders (PBDs) via a dried blood spot-based
      screening method.â€
  - reference: PMID:3119940
    supports: SUPPORT
    snippet: In classic Zellweger syndrome abnormal C27-bile acids, very long chain
      fatty acids, dicarboxylic acids and pipecolic acid accumulate in the plasma
      of the patients.
    explanation: The study mentions the accumulation of C27-bile acids (a type of
      bile acid intermediate) in the plasma of patients with Zellweger syndrome, a
      type of peroxisome biogenesis disorder.
  - reference: PMID:3119940
    supports: SUPPORT
    snippet: In patients with cerebro-hepato-renal (Zellweger) syndrome, the absence
      of peroxisomes results in an impairment of metabolic processes in which peroxisomes
      are normally involved. These include the catabolism of very long chain (greater
      than C22) fatty acids, the biosynthesis of ether-phospholipids and of bile acids,
      the catabolism of phytanic acid and the catabolism of pipecolic acid.
    explanation: The study supports the concept that certain biochemical markers,
      including bile acid intermediates, are elevated due to the metabolic process
      impairments in peroxisome biogenesis disorders.
genetic:
- name: PEX1
  association: Pathogenic Variants
  evidence:
  - reference: PMID:33955040
    supports: SUPPORT
    snippet: Zellweger syndrome (ZS) is the foremost common and severe phenotype within
      the heterogeneous ZSD. However, missense mutations encode proteins with residual
      functions, which are associated with phenotypes that are milder than ZS. Mutations
      in the PEX1 gene are among the most prevalent.
    explanation: The statement is supported as it mentions that mutations in the PEX1
      gene are among the most prevalent causes of Zellweger syndrome, which is a type
      of PBD.
- name: PEX6
  association: Pathogenic Variants
  evidence:
  - reference: PMID:17055079
    supports: SUPPORT
    snippet: Defects in PEX genes impair peroxisome assembly and multiple metabolic
      pathways confined to this organelle, thus providing the biochemical and molecular
      bases of the peroxisome biogenesis disorders (PBD).
    explanation: This statement indicates that mutations in PEX genes, including PEX6,
      are foundational to the development of peroxisome biogenesis disorders.
  - reference: PMID:15858711
    supports: SUPPORT
    snippet: Matsumoto and colleagues recently identified PEX26 as the gene responsible
      for complementation group 8 of the peroxisome biogenesis disorders... Here,
      we identify new PEX26 disease alleles, localize the PEX6-binding domain to the
      N-terminal half of the protein (aa 29-174), and show that, at the cellular level,
      PEX26 deficiency impairs peroxisomal import of both PTS1- and PTS2-targeted
      matrix proteins.
    explanation: This paper discusses PEX26 in detail but also underscores the critical
      function of PEX6 in peroxisome biogenesis.
  - reference: PMID:36980088
    supports: SUPPORT
    snippet: Genetic testing revealed a mutation of the PEX6 (Peroxisomal Biogenesis
      Factor 6) gene, and the metabolic profile was consistent with the diagnosis.
    explanation: This case report directly links pathogenic variants in PEX6 to a
      specific case of peroxisome biogenesis disorder.
  - reference: PMID:33955040
    supports: SUPPORT
    snippet: Autosomal recessive disorder of the Zellweger spectrum (ZSD) is a major
      subset of peroxisome biogenesis disorders (PBDs) that can be caused by mutations
      in any of the 14 PEX genes. ... Mutations in the PEX1 gene are among the most
      prevalent. PEX1 and PEX6 proteins, belonging to the AAA family of ATPases, form
      a hexameric complex, which is associated with peroxisome membranes and essential
      for peroxisome biology.
    explanation: This paper confirms that mutations in PEX6, similar to those in PEX1,
      are linked to peroxisome biogenesis disorders.
  - reference: PMID:10408779
    supports: SUPPORT
    snippet: The PEX6 (peroxisome assembly factor-2, PAF-2) gene... restores peroxisome
      assembly in fibroblasts from peroxisome biogenesis disorder patients belonging
      to complementation group C (group 4 in the United States).
    explanation: This research clarifies the structure and mutations of PEX6, noting
      its role in peroxisome biogenesis disorders.
- name: PEX13
  association: Pathogenic Variants
  notes: PEX13 is part of the docking complex for peroxisomal protein import
- name: PEX26
  association: Pathogenic Variants
  notes: PEX26 anchors the PEX1-PEX6 AAA+ ATPase complex to the peroxisomal membrane
- name: PEX2
  association: Pathogenic Variants
  notes: Part of the RING E3 ubiquitin ligase complex involved in PEX5 ubiquitination
- name: PEX10
  association: Pathogenic Variants
  notes: Part of the RING E3 ubiquitin ligase complex involved in peroxisomal matrix
    protein import
- name: PEX12
  association: Pathogenic Variants
  notes: Part of the RING E3 ubiquitin ligase complex
- name: PEX5
  association: Pathogenic Variants
  notes: PTS1 receptor for peroxisomal protein import
- name: PEX7
  association: Pathogenic Variants
  notes: PTS2 receptor for peroxisomal protein import
- name: Other PEX Genes
  association: Pathogenic Variants
  notes: Approximately 14 PEX genes are known to cause peroxisome biogenesis disorders
    when mutated
  evidence:
  - reference: PMID:10904262
    supports: SUPPORT
    snippet: Recent studies have identified the PEX genes that are mutated in 11 of
      the 12 known complementation groups of PBD patients.
    explanation: This reference indicates that pathogenic variants in other PEX genes
      are associated with Peroxisome Biogenesis Disorder (PBD).
  - reference: PMID:32399598
    supports: SUPPORT
    snippet: For the first time, we show that pathogenic variants in PEX6 can present
      clinically as Perrault syndrome... PEX6 encodes a peroxisomal biogenesis factor.
    explanation: Although this reference primarily discusses Perrault syndrome, it
      confirms that variants in PEX genes such as PEX6 are associated with peroxisomal
      biogenesis disorders.
  - reference: PMID:34804114
    supports: SUPPORT
    snippet: Pathogenic variants in the PEX26 gene lead to peroxisomal disorders of
      the full Zellweger spectrum continuum.
    explanation: This reference highlights PEX26 gene variants contributing to peroxisomal
      disorders which fall under the broader category of peroxisome biogenesis disorders.
  - reference: PMID:29070486
    supports: SUPPORT
    snippet: The biogenesis of peroxisomes requires a category of proteins named peroxins,
      which are encoded by the PEX genes.
    explanation: The reference supports that PEX genes are crucial for peroxisome
      biogenesis, implying that pathogenic variants can lead to related disorders.
environmental:
- name: Not Applicable
  evidence:
  - reference: PMID:26305119
    supports: NO_EVIDENCE
    snippet: In recent years, peroxisomes have emerged as important intracellular
      hubs for redox-, lipid-, inflammatory-, and nucleic acid-mediated signaling
      pathways. In this review, we focus on how nature and nurture modulate peroxisome
      biogenesis and function in mammalian cells.
    explanation: The literature discusses the interplay of genetic, epigenetic, and
      environmental factors in peroxisome biogenesis and function but does not describe
      peroxisome biogenesis disorders as purely environmental.
  - reference: PMID:30656921
    supports: NO_EVIDENCE
    snippet: The disturbance of the peroxisome structure due to mutations in different
      PEX and non-PEX genes coding functional peroxisomal proteins is the pathogenic
      basis of the peroxisomal disorders.
    explanation: The literature explains that peroxisome biogenesis disorders are
      due to genetic mutations, not environmental factors.
treatments:
- name: Symptomatic Management
  description: Supportive care addressing specific symptoms such as physical therapy
    for hypotonia and seizure management.
  evidence:
  - reference: PMID:11060787
    supports: PARTIAL
    snippet: Treatment of PBD patients has generally involved only supportive care
      and symptomatic therapy.
    explanation: The statement about supportive care and symptomatic therapy is accurate
      but does not explicitly mention physical therapy for hypotonia and seizure management.
  - reference: PMID:38409970
    supports: PARTIAL
    snippet: Despite an absence of treatment options, prompt diagnosis of Zellweger
      syndrome is important for providing appropriate symptomatic care.
    explanation: The statement supports symptomatic care but does not detail specific
      treatments such as physical therapy for hypotonia or seizure management.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Nutritional Support
  description: Specialized diet and supplements to manage biochemical abnormalities.
  evidence:
  - reference: PMID:11060787
    supports: SUPPORT
    snippet: A number of experimental therapies have been evaluated to determine whether
      or not correction of biochemical abnormalities through dietary supplementation
      and/or modification is of clinical benefit to PBD patients.
    explanation: This snippet indicates that dietary supplementation and/or modification
      has been evaluated to manage biochemical abnormalities in PBD patients, supporting
      the statement that specialized diet and supplements can be a treatment strategy.
  - reference: PMID:18758655
    supports: SUPPORT
    snippet: The most important measures used to manage the intoxication present in
      many inborn errors of intermediate metabolism were presented (restriction of
      substrate build-up by means of diet or enzymatic inhibition, removal of toxic
      products, stimulation of residual enzyme activity, replacement of the deficient
      product).
    explanation: This reference discusses the use of diet as a measure to manage biochemical
      abnormalities in metabolic disorders, including peroxisomal diseases, which
      supports the statement.
  - reference: PMID:16819396
    supports: NO_EVIDENCE
    snippet: Bile-acid therapy using oral cholic acid has proven effective in most
      of these bile acid synthetic defects making early diagnosis crucial to optimum
      clinical prognosis.
    explanation: While this reference discusses a specific bile-acid therapy, it does
      not provide evidence about dietary or supplemental approaches for managing biochemical
      abnormalities in PBDs.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
- name: Liver Transplant
  description: Considered in severe cases with significant liver dysfunction.
  evidence:
  - reference: PMID:35331403
    supports: SUPPORT
    snippet: Most of these disorders are currently treated by liver transplantation
      as standard of care.
    explanation: The reference indicates that liver transplantation is the standard
      of care for congenital inherited hepatic disorders, which includes peroxisomal
      disorders like Peroxisome Biogenesis Disorder (PBD), supporting that liver transplant
      is considered in severe cases with significant liver dysfunction.
  - reference: PMID:26615381
    supports: PARTIAL
    snippet: ZS should be considered in the list of differential diagnosis in infants
      with stereotypical phenotype, neurodevelopmental delay, and severe hypotonia
      in association with liver and other organs involvement.
    explanation: While this reference confirms liver involvement in Peroxisome Biogenesis
      Disorders such as Zellweger Syndrome, it does not specifically mention liver
      transplantation as a treatment.
  - reference: PMID:22974902
    supports: PARTIAL
    snippet: When none of the liver parenchyma is spared, or kidney insufficiency
      is marked, the only potentially curable treatment is liver transplantation (LT).
    explanation: This reference supports the use of liver transplantation in severe
      liver conditions, though it does not directly mention Peroxisome Biogenesis
      Disorder.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Genetic Counseling
  description: Providing information and support to families regarding inheritance
    and implications.
  evidence:
  - reference: PMID:14619605
    supports: SUPPORT
    snippet: Genetic counseling has developed as a discipline in response to the need
      to educate patients, families and professionals about genetic mechanisms and
      their application in health care. ... Genetic counseling is a process of medical
      education based upon empathy, patient autonomy and confidentiality in an atmosphere
      of empathy, support and understanding.
    explanation: The literature describes genetic counseling as a discipline developed
      to educate patients, families, and professionals about genetic mechanisms and
      their application in healthcare, which supports the statement about providing
      information and support to families regarding inheritance and implications.
  - reference: PMID:30237433
    supports: SUPPORT
    snippet: Furthermore, it is also important to identify pre-symptomatic patients
      by family analysis of probands by providing appropriate disease information
      and genetic counseling, which will also lead to early intervention.
    explanation: The literature discusses the importance of providing disease information
      and genetic counseling to families, supporting the statement about providing
      information and support to families regarding inheritance and implications in
      the context of peroxisomal diseases.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
review_notes: This is a multisystem disorder affecting multiple organ systems due
  to defective peroxisome function. The phenotypes can be quite variable, but neurologic
  and hepatic manifestations are most prominent. Enhanced with recent research (2023-2025)
  highlighting microglial DAM signatures, peroxisome-organelle crosstalk, retinal
  pigment epithelium dysfunction, and detailed PEX gene import machinery. Added biological
  process annotations for fatty acid metabolism, ether lipid biosynthesis, and peroxisome
  organization. Expanded genetic variants to include specific PEX genes (PEX2, PEX5,
  PEX7, PEX10, PEX12, PEX13, PEX26) with functional notes. Added phenotypes including
  seizures, leukodystrophy, cholestasis, and renal dysfunction.
disease_term:
  preferred_term: peroxisome biogenesis disorder
  term:
    id: MONDO:0019234
    label: peroxisome biogenesis disorder
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Peroxisome_Biogenesis_Disorder.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>